Beta Bionics is a biotechnology company that develops an integrated bionic pancreas system called the iLet.
Beta Bionics is a biotechnology company that develops an integrated bionic pancreas system called the iLet. The iLet Bionic Pancreas System was granted breakthrough designation in all configurations (insulin-only, glucagon-only, and bihormonal), including use with Zealand Pharma’s dasiglucagon, a glucagon analog with a unique stability profile in a ready-to-use aqueous solution. It also offers a bionic pancreas device for glucose metabolism to the diabetes community.Beta Bionics was founded in 2015 and is based in Boston, Massachusetts, United States.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Feb 17, 2022 | Series C | $57M | 1 | — | — | Detail |
Jan 8, 2019 | Series B | $63M | 1 | — | — | Detail |
Dec 31, 2015 | Series A | $5M | 1 | Novo Nordisk | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Novo Nordisk | — | Series C |
Dexcom | — | Series B |